Codex DNA, Inc. (DNAY)

NASDAQ: DNAY · Delayed Price · USD
7.26
0.13 (1.82%)
At close: Jan 21, 2022 4:00 PM
7.04
-0.22 (-3.03%)
After-hours:Jan 21, 2022 4:54 PM EST
Market Cap212.77M
Revenue (ttm)9.90M
Net Income (ttm)-32.05M
Shares Out29.31M
EPS (ttm)-2.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume281,186
Open6.97
Previous Close7.13
Day's Range6.86 - 7.39
52-Week Range6.16 - 25.70
Betan/a
AnalystsStrong Buy
Price Target25.00 (+244.4%)
Earnings Daten/a

About DNAY

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building bloc...

IndustryMedical Devices
IPO DateJun 18, 2021
Employees133
Stock ExchangeNASDAQ
Ticker SymbolDNAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Codex DNA stock is "Strong Buy." The 12-month stock price forecast is 25.00, which is an increase of 244.35% from the latest price.

Price Target
$25.00
(244.35% upside)
Analyst Consensus: Strong Buy

News

Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Va...

SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that its R&D team has used the company's proprieta...

3 days ago - GlobeNewsWire

Why Codex DNA Shares Are Trading Higher Today?

Pfizer Inc (NYSE: PFE) has signed on two partners in an effort to become an mRNA powerhouse. Pfizer will offer milestone payments of over $100 million to Codex DNA Inc (NASDAQ: DNAY) for access to the b...

1 week ago - Benzinga

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA's Novel E...

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a leader in the development of automated solutions for on-demand synthesis of genes and mRNA, today announced a strategic col...

1 week ago - GlobeNewsWire

Why Codex DNA Trounced the Market Today

The company's share price blasted 39% higher because of an exciting new partnership.

3 weeks ago - The Motley Fool

Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant

Researchers around the world can utilize the synthetic genome to produce virus to test strain-specific diagnostics, monoclonal antibody treatments, small-molecule therapies, or new vaccines against the ...

4 weeks ago - GlobeNewsWire

Codex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for Bi...

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the commercial launch of its BioXp™ mRNA synthesis...

1 month ago - GlobeNewsWire

Codex DNA to Present at the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief exec...

2 months ago - GlobeNewsWire

Codex DNA Clocks Q3 Sales Growth Of 75%; Acquires Eton Bioscience For $13M

Codex DNA Inc's (NASDAQ: DNAY) Q3 revenues increased 75% Y/Y to $2.8 million. The total fell short of the consensus Wall Street estimate of $2.93 million.

2 months ago - Benzinga

Codex DNA Reports Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the third quarter ended Septe...

2 months ago - GlobeNewsWire

Codex DNA Acquires Eton Bioscience

-- Acquisition will allow Codex DNA to expand its commercial BioXp™ system and biofoundry service offerings, reduce raw material costs, and accelerate overall growth strategy -- -- Acquisition will allo...

2 months ago - GlobeNewsWire

Codex DNA to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its third quarter 2021 financ...

2 months ago - GlobeNewsWire

Codex DNA Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June...

5 months ago - GlobeNewsWire

Codex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 fin...

5 months ago - GlobeNewsWire

Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping Tech

Codex DNA Inc (NASDAQ: DNAY) has announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) for CleanCap technology.  Codex DNA wil...

6 months ago - Benzinga

Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology

Alliance to expand the range of therapeutic and vaccine applications for the BioXp™ system Alliance to expand the range of therapeutic and vaccine applications for the BioXp™ system

6 months ago - GlobeNewsWire

Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Addi...

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY) today announced the closing of its initial public offering of 7,666,664 shares of common stock, including the full exercise of...

6 months ago - GlobeNewsWire

Codex DNA Announces Pricing of Initial Public Offering

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today ...

7 months ago - GlobeNewsWire